Y. Zou
Children's Hospital of Philadelphia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Y. Zou.
American Journal of Medical Genetics Part A | 2005
Janbernd Kirschner; Ingrid Hausser; Y. Zou; Gudrun Schreiber; Hans-Jürgen Christen; Susan C. Brown; Ingrun Anton-Lamprecht; Francesco Muntoni; Folker Hanefeld; Carsten G. Bönnemann
Ullrich congenital muscular dystrophy (UCMD) is caused by mutations in the three genes coding for the alpha chains of collagen VI and characterized by generalized muscle weakness, striking hypermobility of distal joints in conjunction with variable contractures of more proximal joints, and normal intellectual development. The diagnosis is supported by abnormal immunoreactivity for collagen VI on muscle biopsies. As patients with UCMD show clinical characteristics typical of classical disorders of connective tissue such as Ehlers–Danlos syndromes (EDS), we investigated the ultrastructure of skin biopsy samples from patients with UCMD (n=5). Electron microscopy of skin biopsies revealed ultrastructural abnormalities in all cases, including alterations of collagen fibril morphology (variation in size and composite fibers) and increase in ground substance, which resemble those seen in patients with EDS. Our findings suggest that there is a true connective tissue component as part of the phenotypic spectrum of UCMD and that there is considerable clinical as well as morphological overlap between UCMD and classic connective tissue disorders.
Neuromuscular Disorders | 2009
A. Reghan Foley; Y. Hu; Y. Zou; Alexandra B. Columbus; John Shoffner; Diane M. Dunn; Robert B. Weiss; Carsten G. Bönnemann
Mutations in the collagen VI genes (COL6A1, COL6A2 and COL6A3) result in Ullrich congenital muscular dystrophy (CMD), Bethlem myopathy or phenotypes intermediate between Ullrich CMD and Bethlem myopathy. While Ullrich CMD can be caused by either recessively or dominantly acting mutations, Bethlem myopathy has thus far been described as an exclusively autosomal dominant condition. We report two adult siblings with classic Bethlem myopathy who are compound heterozygous for a single nucleotide deletion (exon 23; c.1770delG), leading to in-frame skipping of exon 23 on the maternal allele, and a missense mutation p.R830W in exon 28 on the paternal allele. The parents are carriers of the respective mutations and are clinically unaffected. The exon skipping mutation in exon 23 results in a chain incapable of heterotrimeric assembly, while p.R830W likely ameliorates the phenotype into the Bethlem range. Thus, autosomal recessive inheritance can also underlie Bethlem myopathy, supporting the notion that Ullrich CMD and Bethlem myopathy are part of a common clinical and genetic spectrum.
Neuropediatrics | 2010
J. Schessl; Alexandra B. Columbus; Y. Hu; Y. Zou; T. Voit; Hans H. Goebel; Carsten G. Bönnemann
OBJECTIVEnReducing body myopathy (RBM) is a rare progressive disorder of muscle characterized by intracytoplasmic inclusions, which stain strongly with menadione-NBT (nitroblue tetrazolium). We recently identified the four and a half LIM domain gene FHL1 located on chromosome Xq26 as the causative gene for RBM. So far eight familial cases and 21 sporadic patients with RBM have been reported in the literature.nnnMETHODSnWe ascertained a total of 8 members of a German family initially reported by Goebel et al. as a mixed myopathy with rigid spine myopathy and reducing as well as cytoplasmic bodies. Clinical findings in the original and additional family members have been reviewed. Mutation detection was performed by direct sequencing of FHL1 exons.nnnRESULTSnWe identified a novel mutation (p.C150R) in the second LIM domain of FHL1 in six family members (1 male, 5 females). The male index patient was the most affected member presenting with rigid spine, followed by rapidly progressive muscle weakness. He died from the consequences of respiratory insufficiency at the age of 29.5 years. His sister, mother, grandmother, aunt and female cousin all carried the mutation in the heterozygous state. The sister is clinically unaffected; their mother had myopathic changes in her muscle biopsy, while the grandmother showed first signs of weakness at 50 years of age. The 54-year-old aunt and her daughter are clinically asymptomatic.nnnCONCLUSIONnWe report a novel LIM2 domain mutation in FHL1 in a previously reported family with RBM with cytoplasmic bodies and spinal rigidity. While the male index patient was significantly affected, female carriers show varying manifestations and may be asymptomatic, likely reflecting varying degrees of X-inactivation. RBM continues to be associated with mutations in the LIM2 domain of FHL1. We also confirm our earlier observation that mutations at the N-terminal end of the LIM2 domain seem to be milder compared to mutations seen at the C-terminal part of the domain which cause severe disease even in female carriers.
Annals of Neurology | 2011
A. Reghan Foley; Y. Hu; Y. Zou; Michele Yang; L. Medne; Meganne Leach; Laura K. Conlin; Nancy B. Spinner; Tamim H. Shaikh; Marni J. Falk; Ann M. Neumeyer; Laurie Bliss; Brian Tseng; Thomas L. Winder; Carsten G. Bönnemann
Two mutational mechanisms are known to underlie Ullrich congenital muscular dystrophy (UCMD): heterozygous dominant negatively‐acting mutations and recessively‐acting loss‐of‐function mutations. We describe large genomic deletions on chromosome 21q22.3 as a novel type of mutation underlying recessively inherited UCMD in 2 families. Clinically unaffected parents carrying large genomic deletions of COL6A1and COL6A2also provide conclusive evidence that haploinsufficiency for COL6A1and COL6A2is not a disease mechanism for Bethlem myopathy. Our findings have important implications for the genetic evaluation of patients with collagen VI–related myopathies as well as for potential therapeutic interventions for this patient population. Ann Neurol 2011;69:206–211
Neuromuscular Disorders | 2010
A.R. Foley; Y. Hu; Y. Zou; M. Yang; L. Medne; Meganne Leach; Laura K. Conlin; Nancy B. Spinner; T. Shaikh; Ann M. Neumeyer; Laurie Bliss; T. Winder; Carsten G. Bönnemann
have performed oral function and swallowing test (ST) with surface electrode EMG and videofluoroscopic examination of swallowing (VF) in two unrelated very mild FCMD patients, who were able to walk and step up-down stairs in their childhood. Genomic DNA analysis of these cases showed 3 kb-RT insertion and no mutation in coding region and exon–intron junction of this gene. However, the haplotype analysis of the FKTN gene with six microsatellite markers revealed these patients have different haplotype from other severe type of FCMD. The ST showed severe dysfunction of swallowing in contradiction to their facial appearance and behavioral state. These results indicate that there may be potential risk for dysphagia and the periodical examination of ST is important for keeping the quality of life even in the very mild case of FCMD.
Neuromuscular Disorders | 2009
J. Schessl; Alexandra B. Columbus; Y. Hu; Y. Zou; T. Voit; H.H. Goebel; Carsten G. Bönnemann
Neuromuscular Disorders | 2009
A.R. Foley; Alexandra B. Columbus; J. Schlessl; Y. Hu; Y. Zou; Susan T. Iannaccone; Katherine D. Mathews; Anne M. Connolly; Brenda Wong; Petra Kaufmann; M. Scavina; Kevin M. Flanigan; Robert B. Weiss; R. Finkel; Carsten G. Bönnemann
Neuromuscular Disorders | 2008
Y. Zou; J. Schessl; Carsten G. Bönnemann
Neuromuscular Disorders | 2008
J. Schessl; Y. Zou; Meagan Jane Mcgrath; B.S. Cowling; Baijayanta Maiti; Steven S. Chin; C. Sewry; Roberta Battini; Y. Hu; Denny L. Cottle; Michael M. Rosenblatt; Lynn A. Spruce; Arupa Ganguly; J. Kirschner; Alexander R. Judkins; Jeffrey A. Golden; H.H. Goebel; A.L. Taratuto; Francesco Muntoni; Kevin M. Flanigan; Christina A. Mitchell; Carsten G. Bönnemann
Neuromuscular Disorders | 2006
Y. Zou; Rui-Zhu Zhang; Carsten G. Bönnemann